The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
On Monday, the company is going to announce its first "results" since putting its first and flagship product on shelves. Depending on just which payments are included in the period, it could be the first set of results where the company is in profit.
The market volume is tiny, the share price flags.
No "Friday FOMO" here!
Is it:
A) the market thinks there will be nothing much in the results, too soon to tell and no exciting "forward guidance"?
B) the market has forgotten FUM exists because while eroxon has marketing, FUM is like Red October, slinking through the depths without a sound?
I don't like or even trust companies that focus overly on twitter. But it is necessary to remind people that you're a going concern and it is a basic necessity to have a digital footprint in this digital age.
Maybe Barder is hoping to keep the SP really low so they can implement much cheaper buy-back schemes.
Kudos for the laser-beam focus but now the product is out and rolling out in ever more jurisdictions, its surely time to broaden company activities to include basic corporate activities.
Unless I'm not hearing/understanding this right, in this fireside chat around 07.10 in, to quote what the CEO is saying: We are getting complaints in about one in ten thousand packs sold!!!
I've just managed to access it on my phone(as opposed to my laptop)so will listen this evening with interest.
Unfortunately it seems to be only available via the website.
listening to this interview for the first time, I found it interesting, it address some of the negative feedback from buyers of eroxon.
https://futuramedical.com/investor-centre/videos-and-webcasts/videos/
Laguito and krull.many thanks for the posts.i was still puzzled before krill's post as i listened again and couldnt find it on the you tube webcast.unfortunately i can't view the investor centre one posted by krull due to a problem with my browser.if anyone can post an alternative link (not through future investor centre) i would be grateful.
Thank you Laguito, you made me think again, the mystery is solved, they spoke about it in this presentation, not the other one.
https://futuramedical.com/investor-centre/videos-and-webcasts/webcasts/
A discussion emerges at the Futura Medical Investor Seminar at around the 42 minutes mark where a
member of the audience poses the question of Eroxon’s applicability to women. Ken James responds by
saying that it is a soundly based suggestion. He thinks that Eroxon Stimgel is too thick and a female
version would need to be more lubricating. James Barder confesses to being “acutely aware” of the
need to pursue this line of enquiry. He also reveals that Futura’s marketing partners have asked
questions about this issue. It is clear from James Barder’s demeanor that he has much more “empirical
insight” about this subject than Ken James. At this stage no one has mentioned that MED3000 is “pro-
orgasmic” in women. James Barder did not want to say too much at this stage about what MED3000
does for women. James Barder will wait for the right time to announce Futura’s intentions for
MED3000.
Anyone interested in this subject should watch and listen to the conversation carefully to draw their
own conclusions regarding the likelihood of upcoming clinical studies for MED3000. It is probably
better to watch the video on the Futura website.
P.S The double line gap is due to “glitch” when files are pasted on LSE.
Apologies if this has been mentioned before. Eroxon now available in Tesco Pharmacy.
Regards
Yes quite right The.Italian, I listened to the presentation again, seems my memory was a bit blurred, what they actually talked about, was doing a deal with another company developing a femail sexual health product and dismissing it, there was nothing about developing in house. So I have no idea where Laguito got his information from! I must admit though, It looked genuine to me by the way it was written, also because it would seem quite logical for med3000 to arouse a femail C spot, in the same way as it would the male gland, after thinking more about it, the amount needed to be applied would be much less, so IMO sales for a dedicated femail product would be small, and most likely not worth putting through trials! However, if it does help a women have more fun, then it would surly help boost sales of Eroxon. Maybe someone reading the BB could do some home research and report back, LOL.
Well i have listened to the webcast and i'm afraid(actually im glad) that i didn't hear anything to support the suggestion that futura have any current plans to embark on trials for med 3000 in the area of female sexual health. the sound quality was rather poor,so i may have missed something,but my main take was that fum are currently concentrating(quite rightly imo) on the roll out of med 3000 in its current form. barder mentioned this as the main focus several times,emphasising that the aim was to move from a loss making company to one with positive profit,an objective ofter sadly lacking in many aim companies. in a slightly different context,when responding to a question as to whether fum would contemplate acquiring another aim company(sorry didn't catch the name) which was suggested as being a good fit, barder made it very clear that the did not wish to see them encumbered with debt when they were on the point of becoming csh positive,again a very sensible point of view.he also commented that fum is, in reality,a very small company. further trials etc were clearly not on the current agenda.pleased to hear that australia should get approval without further trials and perhaps we may hear more on this by end of year. so all in all i really don't see any developments of substance in other areas as likely for quite some time.
I don't think anyone will do a take over unless they get an extension on the patent, which expires in 2029. Well they won't get a decent return on a potential buyout. if they get the extension until 2040 then they may.
Also, if I remember rightly, MED3000 is just a formulation of chemicals that anybody can produce. So the patent will need to cover a vast array of formulations to ensure that nobody else can formulate a simiular product (pretty sure I read that from someone on this board...)
Thanks for the link,Krull. appreciated. i will have a listen this evening.
Https://www.youtube.com/watch?v=oWyb285P928&pp=ygUOZnV0dXJhIG1lZGljYWw%3D
It believe it was discussed in this investor presentation towards the end, as I recall, but not word for word as scripted by Laguito
https://youtu.be/BqxLg545np4
Yes,it's all very interesting,but where are the actual links to fum saying all this,or even part of it?can you please post actual links,rather than cut and paste or ostensible"quotes"
Futura are saying: med3000 (eroxon) but will need a bit of tweaking (if you pardon the pun) can arouse the Clitoris
If Eroxon works on woman as well, there's nothing to stop them buying the blue gel and trying it out, they just need to know it can do that as well
I believe the double line gap is an LSE glitch, seems to happen to me, if I start a new line in a post, it shows as a double line gap. His post looks like a cut & paste from information he has found, it's actually quite significant information! Basically, Eroxon can be used on the femail erogenous zone for more pleasure, however, it will need to go though trials and probably need a new name, maybe also a change of colour to pink, and add some flavouring
I don’t know about you, but I found it very laborious trying to read it’s posts, so much so, I gave up after about the 5th double line entry. What’s with the two line approach ?…… I wonder what’s wrong with just a summary, I’m sure many more would be interested in just a summary.
Yes, the blue pill manufacturers would want this product, ether to complement their product, or to stop it being a competitor! They could then call it: Viagra Gel.
Yes ,i think potentially it could be a takeover target. i posted a few days ago,that this might be a welcome outcome for the board for various reasons.however,i think it is going to need a much longer data period re sales etc,before this becomes a realistic possibility.18 months to 2 years at a minimum i would have thought.just my opinion of course.
So many new markets appointed and yet the SP remains hovering around 50p_
Surely FUM is a great target for a takeover?
What is your source of information?
“the universal sex aid for women”
futura have stated their intention of extending the eroxon pipeline and this post is an attempt at
understanding what this 2 nd version of med3000 is all about. this leads to a number of bold
predictions about how events will unfold which every investor should research to form an opinion
about the predictions.
a previous post(med3000 for women #4/ orgasm by deduction) concluded that female orgasmic
disorder(fog) involving women experiencing orgasmic dysfunction would become futura’s main
focus for development. however, this does not mean that fog can be treated with med3000. futura
will use fog as a frame of reference for their clinical studies but quietly move away from the negative
connotation of fog itself.
futura’s intention for med3000 is that it could become a “pro-orgasmic sex-aid” that will be of
interest to most of the sexually active female population in the developed world; the potential
customers for med3000 number in the hundreds of millions. these women are capable of orgasm “by
other means”, but when it comes to sexual intercourse itself, they fail to have an orgasm. this is the
secret, silent, unspoken problem facing most heterosexual couples in the developed world and beyond.
many men live “in denial” of this situation and this is a source of tension in a relationship. futura want
to make things easier for couples who live with the tendency of “orgasmic surplus” for men and an
“orgasmic deficit” for women during sexual intercourse. they want to enable heterosexual couples to
become “lost” in the act of intercourse itself without having to “overthink” what they are doing. futura
intend to make a simple claim for med3000: “helps you achieve orgasm during intercourse”. they
also want to make a second claim for med3000: “helps you achieve a more intense orgasm”. this
second claim will make med3000 appealing to women who currently have no problem achieving
orgasm during intercourse. it will also make it attractive to ******* women who achieve orgasm “by
other means”; so med3000 really is “the universal sex aid for women”.
futura will approach the highly complex subject of the female orgasm from a “mainstream
perspective”; that is to say that they will take the view that the majority of orgasms during intercourse
are triggered by direct or indirect clitoral stimulation (masters and johnson, 1966; hite, 1976). “direct
stimulation” means it is “intentional”; “indirect stimulation” is not intentional, it just “happens” as the
clitoris is indirectly stimulated during the coital act. some researchers estimate that approximately
25% of women always have orgasm from intercourse, while 50% of women achieve orgasm from
intercourse about half the time. about 25% rarely or never achieve orgasm from intercourse, (lloyd,
2005) these estimates understate the situation as many of these orgasms involve direct stimula
Futura will only recruit healthy women into their clinical studies who are capable of orgasm “by other
means” but self report difficulties in achieving orgasm from intercourse alone. They will separate these
women into different groups according to their stated difficulty of achieving orgasm during intercourse.
The clinical endpoint is to demonstrate that MED3000 when applied to the clitoris enhances a woman’s
ability to achieve orgasm during intercourse without direct stimulation. Futura will tell the women “you
must not intentionally stimulate the clitoris during intercourse!” They will also use “orgasm rating
scales” to attempt to evaluate the quality of the orgasm. Futura know that MED3000 when applied to
the clitoris will stimulate the nerves that lie within the tissue. They know that these nerves contain
“vesicles” containing “excitatory neurotransmitters”; these are chemicals which enable nerves to com-
municate with each other. Futura agree with “mainstream” researchers that orgasm from intercourse
alone is by “indirect stimulation” during intercourse(Masters and Johnson, 1966; Hite, 1976). So Fu-
tura’s premise is that MED3000 when applied to the clitoris will “supercharge” the nerves in the clitoris
to the extent where indirect stimulation during intercourse will be sufficient to induce orgasm in most
women.
The observation that Futura are poised to reveal a “pro-orgasmic sex- aid” which will be of interest to
the hundreds of millions of sexually active women in the developed world has profound implications
for investors. This is not a “shame product” destined for an unfortunate minority of the population. Fe-
male celebrities will be proud to be associated with “the universal sex aid for women”; this product
could rapidly become famous throughout the world as most women will be curious to experience its
claims.
The stock market is “forward thinking,”it could see obscure contracts, FDA approval, marketing part-
ners etc; it was not moved. Meanwhile, looking at Futura’s share price, there is no evidence that the
stock market has seen Futura’s latest project. The first dramatic movement in Futura’s share price will
happen when the stock market beholds “The Monster” for the first time, shortly after Futura announce
the clinical studies for MED3000 and the stock market finally perceives the scale of Futura’s ambition.
It will perceive the high probability of success with MED3000 just like it predicted FDA approval etc.
It will see potential sales of GBP 10 billion; then GBP 15 billion and more: no one will really know as
there has never been a consumer health product quite like it. The Futura share price will begin to reflect
the potential magnitude of the world’ s first universal sex aid for women.
Hite, S., 1976. The Hite Report. Macmillan, New York
Lloyd, E., 2005. The Case of the Female Orgasm: Bias in the Science of Evolution. Harvard
Unive